The numbers behind that burden are stark. Diabetic retinopathy, a leading cause of vision loss in working-age adults, is projected to affect roughly 161 million people worldwide by 2045. Age-related macular degeneration, the leading cause of blindness among the elderly, is expected to reach nearly 288 million cases by 2040. Meanwhile, corneal disorders ranging from diabetic corneal neuropathy to dry eye disease and chemical burns impose chronic discomfort and visual impairment on millions more. Current treatments, the review notes, leave significant gaps: retinal laser photocoagulation is invasive and causes scarring, intravitreal anti-VEGF injections are costly and require repeated administration, and many corneal diseases are managed only symptomatically without addressing underlying mechanisms.

Fenofibrate’s ophthalmic story began unexpectedly. The FIELD trial, originally designed to test cardiovascular outcomes in patients with type 2 diabetes, revealed in secondary analyses that fenofibrate reduced the need for first retinal laser treatment and slowed two-step progression on the Early Treatment Diabetic Retinopathy Study scale in patients with pre-existing retinopathy. Strikingly, these benefits appeared disproportionate to any changes in plasma lipids, hinting that the drug was acting through pathways unrelated to cholesterol. The ACCORD Eye study reinforced the signal, showing that fenofibrate combined with simvastatin reduced retinopathy progression, with the greatest benefit in patients whose baseline disease was mild to moderate. The recent LENS trial, a double-blind placebo-controlled study of 1,151 people with non-referable diabetic retinopathy or maculopathy, provided dedicated randomized evidence: fenofibrate significantly reduced progression to referable disease and cut the development of macular edema roughly in half, though it found no significant effect on visual acuity, visual function, or quality of life.

What explains a lipid drug protecting the retina? The review’s mechanistic synthesis centers on PPARα, a nuclear transcription factor that regulates lipid metabolism, inflammation, and mitochondrial homeostasis. In the diabetic retina, fenofibrate appears to suppress NF-κB inflammatory signaling through restoration of sirtuin-1, which deacetylates the p65 NF-κB subunit, forming what researchers describe as a PPARα–SIRT1–NF-κB regulatory axis. The drug also preserves monocyte mitochondrial integrity, preventing the release of mitochondrial DNA that would otherwise activate the cGAS–STING inflammatory pathway and drive retinal leukostasis, the adhesion of white blood cells to retinal capillaries that worsens ischemia. Anti-angiogenic effects operate through both PPARα-dependent suppression of retinal VEGF and a PPARα-independent route involving inhibition of CYP2C enzymes, which lowers levels of the pro-angiogenic lipid metabolite 19,20-epoxydocosapentaenoic acid.

Perhaps the most unifying thread across disease models is mitochondrial protection. Diabetic corneal epithelial cells show reduced oxidative phosphorylation and impaired ATP production, and fenofibrate restored markers of mitochondrial integrity in the corneas of both type 1 and type 2 diabetic mice, changes associated with enhanced epithelial repair. Because dysfunctional mitochondria generate reactive oxygen species, release mitochondrial DNA, and amplify NF-κB activation, restoring their function may simultaneously dampen inflammation, oxidative stress, and the angiogenic signaling downstream of both. The review suggests fenofibrate functions less as a single-target drug and more as a pathway-modifying agent that interrupts interconnected cycles of metabolic dysfunction, inflammatory amplification, neovascularization, and fibrosis.

The corneal findings are among the most intriguing. In diabetic corneal neuropathy, a condition in which progressive nerve degeneration impairs epithelial healing and corneal sensitivity, oral fenofibrate for 30 days significantly improved corneal nerve fiber density and width in patients with type 2 diabetes, alongside improvements in tear break-up time and epithelial cell morphology. Tear proteomic analyses revealed upregulation of neurotrophin signaling and increased levels of glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor within the corneal epithelium, both implicated in nerve regeneration. Topical fenofibrate formulations produced even earlier improvements in diabetic mice, raising tear levels of nerve growth factor and substance P that oral treatment did not. In dry eye disease models, fenofibrate restored corneal microvillar architecture through PPARα-dependent regulation of lipid metabolism and suppressed inflammatory signaling in lacrimal glands subjected to chronic intermittent hypoxia.

For corneal chemical burns, which cost US emergency departments roughly $106.7 million over four years, preclinical studies show that topical fenofibrate reduced inflammatory cell infiltration, suppressed corneal neovascularization, and limited stromal fibrosis by reducing α-SMA-positive myofibroblasts and type III collagen deposition. In Fuchs endothelial corneal dystrophy, where no disease-modifying treatment exists and corneal transplantation remains the only option for advanced disease, fenofibrate attenuated TGF-β-induced fibrotic changes in cultured endothelial cells and preserved corneal endothelial morphology in vivo, apparently by enhancing fatty acid oxidation and mitochondrial homeostasis. Even in models of central retinal artery occlusion, an ophthalmic emergency with no established neuroprotective therapy, fenofibrate preserved electroretinographic function, partly through a liver-mediated pathway involving increased circulating fibroblast growth factor 21.

The review is careful about where the evidence stands. Clinical support is strongest for diabetic retinopathy, where randomized trials consistently show that fenofibrate, mostly as an adjunct to statin therapy, slows progression of mild-to-moderate pre-existing disease. Evidence for diabetic corneal neuropathy is preliminary but promising, drawn from small open-label studies without placebo controls. For dry eye disease, corneal burns, Fuchs dystrophy, neovascular age-related macular degeneration, and retinal ischemic injury, the data remain entirely preclinical. Notably, the picture for established diabetic macular edema is inconsistent: while LENS showed clear prevention of incident macular edema in early disease, the MacuFEN trial found no significant benefit of fenofibric acid in eyes with established, treatment-eligible edema. The pattern suggests fenofibrate works best as an early, progression-modifying therapy rather than a rescue treatment for advanced pathology.

Durability poses another unresolved question. Follow-up data from ACCORDION showed that the retinal protective benefit did not persist three to five years after fenofibrate was discontinued, implying that ongoing therapy may be required to maintain any disease-modifying effect. Safety considerations also matter for long-term ophthalmic use: modest reversible increases in serum creatinine are well described, dose reduction is recommended in renal impairment, and liver enzyme monitoring is advised, though long-term trials paradoxically showed slower eGFR decline and reduced albuminuria progression, suggesting a net renoprotective effect. No rhabdomyolysis cases were reported in ACCORD or FIELD, and fenofibrate is considered safer than gemfibrozil in combination with statins.

Emerging drug delivery platforms may ultimately resolve the tension between systemic exposure and ocular efficacy. Fenofibrate-loaded PLGA nanoparticles achieved sustained intraocular delivery and reduced vascular leakage and neovascularization in preclinical models, while long-acting microparticles provided at least six months of intravitreal release from a single injection. A nano-emulsion eye drop achieved higher retinal, choroidal, and corneal drug levels than systemic administration while suppressing retinal inflammation and laser-induced choroidal neovascularization. These formulations remain experimental, and questions of ocular pharmacokinetics, tissue penetration, and long-term safety await answers. Still, the review’s authors argue that fenofibrate represents a biologically plausible adjunctive therapy whose full therapeutic role, beyond diabetic retinopathy, now depends on adequately powered randomized trials, mechanistic validation, and careful pharmacokinetic evaluation. If those efforts succeed, a fifty-year-old cholesterol pill may find itself prescribing a new future for sight.

Subject of Research: Therapeutic repurposing of the PPARα agonist fenofibrate for corneal and retinal diseases

Article Title: Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms

Article References: Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms. (n.d.). https://doi.org/10.3389/jpps.2026.16995

Image Credits: AI Generated

DOI: 10.3389/jpps.2026.16995

Keywords: fenofibrate, PPAR alpha, diabetic retinopathy, diabetic macular edema, diabetic corneal neuropathy, dry eye disease, age-related macular degeneration, drug repurposing, mitochondrial dysfunction, NF-kB signaling, ocular drug delivery, LENS trial